Anabolic Steroids for Nutritional Rehabilitation of Critically Ill Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00242463|
Recruitment Status : Terminated (drug no longer available in canada)
First Posted : October 20, 2005
Last Update Posted : January 5, 2011
|Condition or disease||Intervention/treatment||Phase|
|Malnutrition Critical Illness||Drug: Nandrolone (anabolic steroid) Drug: Placebo||Phase 2|
Critically ill patients are particularly prone to excessive catabolism using skeletal muscle as the primary substrate as a result of maladaptation to critical illness. Ultimately, critical illness leads to a significant loss of lean body mass (LBM). For example, a 40% loss of LBM is associated with a 100% mortality. Anabolic steroids have been studied and have been shown to improve nutrition in select malnourished patient groups, however, the majority of these studies were not well designed or consisted of small sample sizes.
Our hypothesis is anabolic steroid administration will result in an augmentation of positive nitrogen balance and LBM. This increase in LBM will result in liberation from mechanical ventilation sooner than the placebo group and will result in discharge from the ICU sooner, and as a result, a reduction in morbidity (nosocomial infections) and possibly mortality.
All moderately to severly malnourished ICU patients who have an anticipated stay in ICU > 10 days, will be randomized to receive nandrolone (25 mg-females, 50 mg;males) once weekly for six weeks or placebo. All patients will receive a standard enteral nutritional regimen. Patients will be monitored for assessment of nitrogen balance, lean body mass, and length of time spent on ventilator, in ICU and in HOSP, and incidence of infections.Lean body mass will be measured using a bioimpedance analyzer.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||The Efficacy of Anabolic Steroids for the Nutritional Rehabilitation of Critically Ill Patients|
|Study Start Date :||October 2005|
|Actual Primary Completion Date :||October 2007|
|Actual Study Completion Date :||October 2007|
Patients receive weekly injections of nandrolone
|Drug: Nandrolone (anabolic steroid)|
|Placebo Comparator: Placebo||Drug: Placebo|
- Nitrogen Balance
- Lean body mass
- serum prealbumin
- length of stay on ventilator, in ICU, in HOSPITAL
- infectious complications
- outcome (mortality)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00242463
|London Health Sciences Centre-UC|
|London, Ontario, Canada, N6A5A5|
|Principal Investigator:||Michael D Sharpe, MD FRCPC||London Health Sciences Centre-UC|